Found: 29
Select item for more details and to access through your institution.
Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer.
- Published in:
- Journal of Pharmacy Practice, 2024, v. 37, n. 6, p. 1258, doi. 10.1177/08971900241247653
- By:
- Publication type:
- Article
Pharmaceutical Care for Patients Undergoing S-1 Plus Cisplatin Therapy for Unresectable Recurrent Gastric Cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Inhibition of Tumor Necrosis Factor-Alpha and lnterleukin-1-Beta Production by Beta-Adrenoceptor Agonists from Lipopolysaccharide- Stimulated Human Peripheral Blood Mononuclear Cells.
- Published in:
- Pharmacology, 1997, v. 54, n. 3, p. 144, doi. 10.1159/000139481
- By:
- Publication type:
- Article
Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma.
- Published in:
- Journal of Oncology Pharmacy Practice, 2023, v. 29, n. 7, p. 1637, doi. 10.1177/10781552221145475
- By:
- Publication type:
- Article
The incidence and timing of leukocyte overshoot after pegfilgrastim administration.
- Published in:
- Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 4, p. 869, doi. 10.1177/1078155218769140
- By:
- Publication type:
- Article
Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 403, doi. 10.1177/1078155217707335
- By:
- Publication type:
- Article
Evaluation of the role and usefulness of a pharmacist outpatient service for patients undergoing monotherapy with oral anti-cancer agents.
- Published in:
- Journal of Oncology Pharmacy Practice, 2017, v. 23, n. 6, p. 413, doi. 10.1177/1078155216655473
- By:
- Publication type:
- Article
Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.
- Published in:
- International Journal of Cancer, 2024, v. 155, n. 5, p. 849, doi. 10.1002/ijc.34962
- By:
- Publication type:
- Article
Immunomodulatory Action of Levofloxacin on Cytokine Production by Human Peripheral Blood Mononuclear Cells.
- Published in:
- Chemotherapy (0009-3157), 1996, v. 42, n. 6, p. 459, doi. 10.1159/000239480
- By:
- Publication type:
- Article
Usefulness of a pharmacist outpatient service for S-1 adjuvant chemotherapy in patients with gastric cancer.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 7, n. 3, p. 486, doi. 10.3892/mco.2017.1337
- By:
- Publication type:
- Article
Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 7, n. 1, p. 125, doi. 10.3892/mco.2017.1278
- By:
- Publication type:
- Article
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 6, n. 6, p. 955, doi. 10.3892/mco.2017.1232
- By:
- Publication type:
- Article
Pharmaco-economic analysis of adjuvant chemotherapy for stage II and III colorectal cancer.
- Published in:
- Molecular & Clinical Oncology, 2017, v. 6, n. 5, p. 794, doi. 10.3892/mco.2017.1218
- By:
- Publication type:
- Article
Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.
- Published in:
- Molecular & Clinical Oncology, 2016, v. 5, n. 5, p. 635, doi. 10.3892/mco.2016.1020
- By:
- Publication type:
- Article
Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer.
- Published in:
- Molecular & Clinical Oncology, 2016, v. 5, n. 3, p. 283, doi. 10.3892/mco.2016.940
- By:
- Publication type:
- Article
Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting.
- Published in:
- Molecular & Clinical Oncology, 2016, v. 4, n. 4, p. 591, doi. 10.3892/mco.2016.738
- By:
- Publication type:
- Article
Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer.
- Published in:
- Molecular & Clinical Oncology, 2014, v. 2, n. 3, p. 466, doi. 10.3892/mco.2014.260
- By:
- Publication type:
- Article
Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B.
- Published in:
- Experimental & Therapeutic Medicine, 2014, v. 7, n. 4, p. 941, doi. 10.3892/etm.2014.1534
- By:
- Publication type:
- Article
Potential drug interaction between paclitaxel and clopidogrel.
- Published in:
- Biomedical Reports, 2016, v. 5, n. 1, p. 141, doi. 10.3892/br.2016.685
- By:
- Publication type:
- Article
Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 3, p. 383, doi. 10.1007/s00280-020-04126-9
- By:
- Publication type:
- Article
Evaluation of Atezolizumab Plus Bevacizumab Versus Modified Lenvatinib Therapy in Child-Pugh A Unresectable Hepatocellular Carcinoma.
- Published in:
- Cancer Diagnosis & Prognosis, 2024, v. 4, n. 2, p. 122, doi. 10.21873/cdp.10297
- By:
- Publication type:
- Article
Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: A preliminary study.
- Published in:
- Oncology Letters, 2023, v. 25, n. 4, p. N.PAG, doi. 10.3892/ol.2023.13736
- By:
- Publication type:
- Article
Elucidation of optimal proteinuria management based on the risk of ramucirumab-induced proteinuria.
- Published in:
- Oncology Letters, 2022, v. 23, n. 2, p. N.PAG
- By:
- Publication type:
- Article
Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting.
- Published in:
- Oncology Letters, 2015, v. 9, n. 5, p. 2341, doi. 10.3892/ol.2015.3027
- By:
- Publication type:
- Article
Oral anticancer agent medication adherence by outpatients.
- Published in:
- Oncology Letters, 2014, v. 8, n. 5, p. 2318, doi. 10.3892/ol.2014.2480
- By:
- Publication type:
- Article
A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma.
- Published in:
- Molecular & Clinical Oncology, 2020, v. 12, n. 3, p. 284, doi. 10.3892/mco.2020.1978
- By:
- Publication type:
- Article
Tolerability and safety of real-world use of pomalidomide in patients with relapsed/refractory multiple myeloma.
- Published in:
- Molecular & Clinical Oncology, 2019, v. 10, n. 2, p. 293
- By:
- Publication type:
- Article
Effect of the timing of discontinuation of last-line chemotherapy on patient prognosis in advanced and recurrent gastric cancer.
- Published in:
- Molecular & Clinical Oncology, 2019, v. 10, n. 1, p. 173
- By:
- Publication type:
- Article
Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database.
- Published in:
- Medicina (1010660X), 2023, v. 59, n. 11, p. 1963, doi. 10.3390/medicina59111963
- By:
- Publication type:
- Article